CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
SCD-F40device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02820350
NCT02820350N/ACompleted
CompareCT.gov

A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI)

CytoPherx, Inc·interventional·Posted Jun 30, 2016·Updated Jun 20, 2024

In Brief

A clinical study evaluating SCD-F40 for Acute Kidney Injury. Completed, enrolled 19 participants across 4 sites.

Detailed Summary

The SCD (Selective Cytopheretic Device) is an extracorporeal device used as an adjunct to renal replacement therapy (RRT) to improve the outcomes of pediatric patients with acute kidney injury (AKI). Funding Source - FDA OOPD (SCD-PED-01)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Kidney Injury
CountriesUnited States
CollaboratorsInnovative BioTherapies (IBT), Children's Hospital Medical Center, Cincinnati

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 30, 2016
Enrollment StartDec 4, 2016
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.0 years ago

Interventions

SCD-F40device

CRRT with SCD